Sanofi layoffs cut total US sales forces to 5,700

Share this article:

Sanofi-Aventis laid off 400 reps last Monday, as part of a strategy to focus on key therapeutic areas moving forward. Total company sales forces in the US number 5,700 as a result of the cuts.

Emmy Tsui, a Sanofi spokesperson, said key therapeutic areas for the company include "diabetes, oncology, atrial fibrillation, and other platforms for sustainable growth." Tsui added that Sanofi will "continue to evaluate the resources we have dedicated to our US operations," but would not comment directly on plans for future changes to US sales forces.

In a letter to Sanofi employees published on BNET, Jerry Durso, Sanofi VP and head of US specialized therapeutics, said the cuts were related to a "reduced presence in the CNS market," which includes Ambien CR and Aplenzin, an outsourcing of reps on bone drug Actonel, and a reduced sales force behind Nasacort AQ. Sales of Nasacort AQ were $239 million in 2009, around $50 million higher than Sanofi's next-generation allergy drug Xyzal, according to SDI figures. Nasacort AQ, however, is expected to face generic competition as early as summer of 2011.

Marketing rights for Actonel, a treatment for osteoporosis, were handed off to Warner Chilcott, Sanofi's collaborator on the drug. As part of the deal, Warner Chilcott will offer an undisclosed number of jobs to Sanofi reps previously working on the brand. Actonel sales declined to $264 million in 2009, despite a 39% price hike between 2006 and 2010, an increase Sen. Bill Nelson (D-FL) called "egregious" during a Senate committee meeting in March.      

In keeping with the decision to focus on diabetes as one key area for growth, Sanofi announced yesterday that it had acquired exclusive worldwide licensing rights for Pancreate, a diabetes type 1 and 2 treatment developed by CureDM, a Delaware-based biopharma. Pancreate (proisletide acetate) is thought to stimulate the production of insulin-producing islets in the pancreas, and is expected to enter stage 1 clinical trials later this year. The deal includes a potential $335 million in milestone payments to CureDM, should the drug successfully enter the market, according to a company statement.
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Channel


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...